Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) FLT3 Antibodies:
anti-Human FLT3 Antibodies:
anti-Rat (Rattus) FLT3 Antibodies:
Go to our pre-filtered search.
Human Monoclonal FLT3 Primary Antibody for FACS - ABIN2688960
Mackarehtschian, Hardin, Moore, Boast, Goff, Lemischka: Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. in Immunity 1995
Show all 4 Pubmed References
Human Polyclonal FLT3 Primary Antibody for CyTOF, FACS - ABIN4900037
Armstrong, Kung, Mabon, Silverman, Stam, Den Boer, Pieters, Kersey, Sallan, Fletcher, Golub, Griffin, Korsmeyer: Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. in Cancer cell 2003
Show all 2 Pubmed References
Human Polyclonal FLT3 Primary Antibody for IF - ABIN362818
Sekine, Kataoka, Fukuyama, Adachi, Davydova, Yamamoto, Kobayashi, Fujihashi, Suzuki, Curiel, Shizukuishi, McGhee, Fujihashi: A novel adenovirus expressing Flt3 ligand enhances mucosal immunity by inducing mature nasopharyngeal-associated lymphoreticular tissue dendritic cell migration. in Journal of immunology (Baltimore, Md. : 1950) 2008
Show all 5 Pubmed References
Human Monoclonal FLT3 Primary Antibody for IHC, ELISA - ABIN1724846
Pereira de Sousa, Berthault, Granato, Dias, Ramond, Kee, Cumano, Vieira: Inhibitors of DNA binding proteins restrict T cell potential by repressing Notch1 expression in Flt3-negative common lymphoid progenitors. in Journal of immunology (Baltimore, Md. : 1950) 2012
Show all 2 Pubmed References
Human Monoclonal FLT3 Primary Antibody for FACS, IP - ABIN489931
Kuchenbauer, Kern, Schoch, Kohlmann, Hiddemann, Haferlach, Schnittger: Detailed analysis of FLT3 expression levels in acute myeloid leukemia. in Haematologica 2005
Show all 5 Pubmed References
Human Monoclonal FLT3 Primary Antibody for FACS, IP - ABIN1302921
Whartenby, Calabresi, McCadden, Nguyen, Kardian, Wang, Mosse, Pardoll, Small: Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. in Proceedings of the National Academy of Sciences of the United States of America 2005
Show all 5 Pubmed References
Mouse (Murine) Polyclonal FLT3 Primary Antibody for CyTOF, FACS - ABIN4900092
Arora, Stopp, Böhmer, Schons, Godfrey, Masson, Razumovskaya, Rönnstrand, Tänzer, Bauer, Böhmer, Müller: Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling. in The Journal of biological chemistry 2011
Human Monoclonal FLT3 Primary Antibody for CyTOF, FACS - ABIN4900035
Williams, Li, Nguyen, Brown, Levis, Small: Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. in Blood 2012
ATM (show ATM Antibodies)/G6PD (show G6PD Antibodies)-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia (show BCL11A Antibodies) that can be successfully reversed.
Flt3 and cooperating Flt3/Runx1 mutations cause hematopoietic stem cell depletion and myeloid progenitor expansion during adult but not fetal stages of murine development.
Tumor necrosis factor (TNF (show TNF Antibodies)), a cell-extrinsic potent negative regulator of hematopoietic stem cells (HSCs), was overexpressed in bone marrow niche cells from FLT3 internal tandem duplications (FLT3 ITDs) mice.
the angiogenic factor (show VEGFA Antibodies) Egfl7 (show EGFL7 Antibodies) activates the Flt3/Flt3 ligand (show FLT3LG Antibodies) pathway and is a key molecular driver enforcing thymus progenitor generation and thereby directly links endothelial cell biology to the production of T cell-based adaptive immunity
the Hoxa9 (show HOXA9 Antibodies)- and Meis1 (show MEIS1 Antibodies)-associated upregulation of Flt3 is a passive event with regard to leukemia development in mice and with limited relevance to the AML (show RUNX1 Antibodies) pathology.
lineage-specific STAT5 (show STAT5A Antibodies) activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype in mice
DOCK2 (show DOCK2 Antibodies) is a potential therapeutic target for novel AML (show RUNX1 Antibodies) treatments, as this protein regulates the survival of leukemia cells with elevated FLT3 activity and sensitizes FLT3/ITD leukemic cells to conventional antileukemic agents.
Used a genetic model to determine whether miR (show MLXIP Antibodies)-155 influences the development of FLT3-ITD-induced myeloproliferative disease. miR (show MLXIP Antibodies)-155 promotes FLT3-ITD-induced myeloid expansion in the bone marrow, spleen, and peripheral blood. Mechanistically, miR (show MLXIP Antibodies)-155 increases proliferation of the hematopoietic stem and progenitor cell compartments by reducing the growth-inhibitory effects of the interferon (show IFNA Antibodies) response.
Overexpression of Abl (show ABL1 Antibodies)-related gene tyrosine kinase (show TYRO3 Antibodies) ABL2 in pro-B cell line Ba/F3 cells expressing an oncogenic mutant of FLT3 (FLT3-ITD) resulted in partial inhibition of FLT3-ITD-dependent cell proliferation.
Sorafenib-resistant leukemia cells with a FLT3/ITD mutation are sensitive to glycolytic inhibitors.
a decision analysis comparing allo-HCT vs chemotherapy in first complete remission for patients with cytogenetically intermediate-risk acute myeloid leukemia (show BCL11A Antibodies), depending on the presence or absence of FLT3-ITD), NPM1 (show NPM1 Antibodies), and CEBPA (show CEBPA Antibodies) mutations showed that allo-HCT was a favored postremission strategy in patients with FLT3-ITD, and chemotherapy was favored in patients with biallelic CEBPA (show CEBPA Antibodies) mutations.
Data suggest that there is a place for escalated daunorubicin dosing for fms-like tyrosine kinase 3 (FLT3)-ITD mutated cases.
Integrin alphavbeta3 (show ITGAV Antibodies) has a role in enhancing beta-catenin (show CTNNB1 Antibodies) signaling in acute myeloid leukemia (show BCL11A Antibodies) harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations
Review of the role of the most common form of FMS-like tyrosine kinase 3 (FLT3) mutation (internal tandem duplication) in acute myeloid leukemia (show BCL11A Antibodies).
the present cohort study demonstrated that FLT3-ITD and DNMT3A (show DNMT3A Antibodies) R882 double mutation predicts poor prognosis in Chinese AML (show RUNX1 Antibodies) patients receiving chemotherapy or allo-HSCT treatment.
Although transient responses to FLT3 inhibitors are often observed in case of disease relapse, the most promising approach is the use of FLT3 inhibitors either in combination with induction chemotherapy or as consolidation/maintenance therapy after allogeneic hematopoietic cell transplantation.
In this review, we focus on three key areas in acute myeloid leukemia (show BCL11A Antibodies) (AML (show RUNX1 Antibodies)) developmental therapeutics: FLT3 inhibitors, IDH(IDH1 (show IDH1 Antibodies) and IDH2 (show IDH2 Antibodies) ) inhibitors, and drugs that may be particularly beneficial in secondary AML (show RUNX1 Antibodies)
Concomitant monitoring of WT1 (show WT1 Antibodies) and FLT3-ITD expression in FLT3-ITD acute myeloid leukemia (show BCL11A Antibodies) patients
FLT3/ITD are present at leukemic stem cells level and may be a primary and not secondary event in leukemogenesis, and the oncogenic events of FLT3/ITD happen at a cell stage possessing CD123 (show IL3RA Antibodies)
This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. The receptor consists of an extracellular domain composed of five immunoglobulin-like domains, one transmembrane region, and a cytoplasmic kinase domain split into two parts by a kinase-insert domain. The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.
fms-related tyrosine kinase 3
, FL cytokine receptor-like
, FL cytokine receptor
, fetal liver kinase 2
, receptor-type tyrosine-protein kinase FLT3
, tyrosine-protein kinase FLT3
, tyrosine-protein kinase receptor flk-2
, CD135 antigen
, fms-like tyrosine kinase 3
, growth factor receptor tyrosine kinase type III
, stem cell tyrosine kinase 1
, FMS-like tyrosine kinase 3